A seminal study demonstrated that mutational burden in the genomic region containing TP53 was comparable between t‐AML and de novo AML, suggesting that it was unlikely that chemotherapy directly induced the TP53mut [32]. This evidence concerns the gene TP53 and acute myeloid leukemia.